Female balb c

Female BALB/c (non-tumor bearing) mice at 4–6 weeks of age (Taconic, USA) were utilized for toxicity experiments (at MIT). Female NCR nu/nu mice at 5 weeks of age were used for pharmacology and efficacy experiments upon establishment of a disseminated cell-line xenograft model of HGSOC (8 × 10⁵ LUC⁺/RFP⁺ OVCAR8 cells/animal; 0.5 mL; IP injection) and were similarly purchased from Taconic. C.B-17/Icr-SCID/Sed mice were purchased from Charles River and bred at MGH; they were implanted with primary cells obtained from a patient with “platinum-resistant” and advanced-stage HGSOC after lentiviral transduction of firefly luciferase, establishing LUC⁺ PDX tumors (10 million cells/animal; 0.5 mL PBS; IP injection); assessments of CNP(MMAE) pharmacology and efficacy were performed in these PDX models. Tumor growth was monitored by BLI. All animal studies were performed under protocols approved by the MIT CAC (0615-069-1) and by the Massachusetts General Hospital IACUC (2009N000117).

Female BALB/c and C57BL/6 mice (6–8 weeks old) were purchased from Taconic Farms. Animals were housed in specific pathogen–free conditions in a vivarium (5 mice per cage), and all experiments were performed under Institutional Animal Care and Use Committee (IACUC) approved protocols and guidelines at Avastus Preclinical Services (Cambridge, MA). Mice were allowed to acclimate in the vivarium for 1–2 weeks prior to the start of experiments. Mice were monitored daily, provided PicoLab Rodent Diet 20 and autoclaved water ad libitum.